Claims
- 1. An isolated nucleic acid molecule comprising a polynucleotide having a sequence selected from the group consisting of:
(a) a sequence encoding amino acids from about 1 to about 744 of SEQ ID NO:3; (b) a sequence encoding amino acids from about 2 to about 744 of SEQ ID NO:3; (c) a sequence encoding amino acids from about 1 to about 691 of SEQ ID NO:6; (d) a sequence encoding amino acids from about 2 to about 691 of SEQ ID NO:6; (e) a sequence encoding amino acids from about 1 to about 724 of SEQ ID NO:9; (f) a sequence encoding amino acids from about 2 to about 724 of SEQ ID NO:9; (g) a sequence encoding amino acids from about 1 to about 795 of SEQ ID NO:12; (h) a sequence encoding amino acids from about 2 to about 795 of SEQ ID NO:12; (i) complements of the sequences of (a)-(h); (j) a sequence having 50-2232 contiguous nucleotides from the coding region of SEQ ID NO:1; (k) a sequence having 50-2073 contiguous nucleotides from the coding region of SEQ ID NO:4; (l) a sequence having 50-2172 contiguous nucleotides from the coding region of SEQ ID NO:7; (m) a sequence having 50-2385 contiguous nucleotides from the coding region of SEQ ID NO:10; (n) sequences having at least 90% identity to the sequences of (a)-(m); (o) sequences having 100-1500 contiguous nucleotides from the coding region of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 or SEQ ID NO:10; (p) sequences having 500-1000 contiguous nucleotides from the coding region of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 or SEQ ID NO:10; (r) sequences of (a)-(h), except for at least one amino acid substitution in the encoded amino acid sequence; and (s) sequences of (a)-(h), expect for a conversion of a conserved lysine to an alanine at an ATP binding site of the encoded amino acid sequence.
- 2. A method of making a vector comprising inserting a nucleic acid molecule of claim 1 into said vector in operable linkage to a promoter.
- 3. A vector produced by the method of claim 2.
- 4. A method of making a host cell comprising transforming or transfecting a vector of claim 3 into a cell.
- 5. A host cell produced by the method of claim 4.
- 6. A method of making a polypeptide, comprising culturing the host cell of claim 5 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 7. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- 8. An epitope-bearing portion of a polypeptide selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:12.
- 9. The epitope-bearing portion of claim 8, which comprises about 5 to about 50 contiguous amino acids.
- 10. An isolated antibody that binds to the polypeptide of claim 7.
- 11. A complex comprising a polypeptide of claim 7 and a Dishevelled protein.
- 12. A complex comprising a fragment of a polypeptide of claim 7 and a Dishevelled protein.
- 13. A method of identifying an inhibitor or enhancer of PAR-1phosphorylation activity, comprising:
(a) contacting a cell transfected with at least an expression vector encoding Wnt with a candidate inhibitor or enhancer; and (b) detecting an increase or decrease in Dsh phosphorylation, wherein a decrease in Dsh phosphorylation indicates the presence of an inhibitor and an increase in Dsh phosphorylation indicates the presence of an enhancer.
- 14. An isolated PAR-1 modulator selected from the group consisting of an antisense oligonucleotide, a ribozyme, a protein, a polypeptide, and a small molecule.
- 15. The isolated PAR-1 modulator of claim 14, wherein said PAR-1modulator is an antisense molecule or the complement thereof.
- 16. The isolated PAR-1 modulator of claim 15, wherein said antisense molecule or the complement thereof has at least 15 consecutive nucleic acids of the sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 or SEQ ID NO:12 or which hybridizes under high stringency conditions to said at least 15 consecutive nucleic acids of the sequence of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 or SEQ ID NO:12.
- 17. The isolated PAR-1 modulator of claim 15, wherein said antisense molecule is selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17.
- 18. The isolated PAR-1 modulator of claim 14, wherein said PAR-1 modulator is selected from the group consisting of an antibody and an antibody fragment.
- 19. The isolated PAR-1 modulator of claim 14, wherein said polypeptide has an amino sequence with at least 95% identity to the amino acid sequence provided in SEQ ID NO:22.
- 20. A composition, comprising a therapeutically effective amount of a PAR-1modulator of claim 14 in a pharmaceutically acceptable carrier.
- 21. A method of treating a mammal with a disease or disorder associated with a PAR-1 polypeptide, comprising administering to the mammal a composition including a therapeutically effective amount of a PAR-1 modulator of claim 14.
- 22. The method of claim 23, wherein said PAR-1 modulator is an antisense molecule is selected from the group consisting of SEQ ID NO:13, SEQ ID NO:15 and SEQ ID NO:17.
- 23. The method of claim 21, wherein said PAR-1 modulator is a polypeptide that has an amino sequence with at least 95% identity to the amino acid sequence provided in SEQ ID NO:22.
- 24. The method of claim 21, wherein said PAR-1 modulator is selected from the group consisting of an antibody and an antibody fragment.
- 25. The method of claim 21, wherein said PAR-1 modulator is administered ex vivo to said mammalian cell.
CROSS REFERENCE TO RELATION APPLICATION
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/221,860 filed Jul. 28, 2000, where this provisional application is incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60221860 |
Jul 2000 |
US |